Premium
Epidemiology of basal cell carcinoma: scholarly review
Author(s) -
Verkouteren J.A.C.,
Ramdas K.H.R.,
Wakkee M.,
Nijsten T.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15321
Subject(s) - basal cell carcinoma , incidence (geometry) , epidemiology , medicine , skin cancer , germline mutation , health care , field cancerization , disease , dermatology , cancer , basal cell , mutation , genetics , biology , political science , physics , law , optics , gene
Summary Basal cell carcinoma ( BCC ) is the most common cancer in white‐skinned individuals with increasing incidence rates worldwide. Patients with BCC place a large burden on healthcare systems, because of the high incidence and the increased risk of synchronous and metachronous BCC s and other ultraviolet radiation ( UVR ) related skin cancers (i.e. field cancerization). As a result, the disability‐adjusted life years and healthcare costs have risen significantly in recent decades. BCC is a complex disease, in which the interplay between UVR , phenotype ( UVR ‐sensitive) and genotype (somatic mutations and germline mutations/polymorphisms) fulfils a key role in the aetiopathogenesis. Prevention programmes with continual refinements and improvements could be of major importance in tackling the growing skin cancer problem. To provide the most appropriate BCC care, physicians should engage in shared decision‐making and choose their treatments wisely.